JP2022536935A5 - - Google Patents

Info

Publication number
JP2022536935A5
JP2022536935A5 JP2021574918A JP2021574918A JP2022536935A5 JP 2022536935 A5 JP2022536935 A5 JP 2022536935A5 JP 2021574918 A JP2021574918 A JP 2021574918A JP 2021574918 A JP2021574918 A JP 2021574918A JP 2022536935 A5 JP2022536935 A5 JP 2022536935A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hiv
cells
once
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021574918A
Other languages
English (en)
Japanese (ja)
Other versions
JP7612617B2 (ja
JP2022536935A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038177 external-priority patent/WO2020257309A1/en
Publication of JP2022536935A publication Critical patent/JP2022536935A/ja
Publication of JP2022536935A5 publication Critical patent/JP2022536935A5/ja
Application granted granted Critical
Publication of JP7612617B2 publication Critical patent/JP7612617B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021574918A 2019-06-17 2020-06-17 細胞性免疫及び体液性免疫を誘導するための同種異系t細胞ベースのhivワクチン Active JP7612617B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862432P 2019-06-17 2019-06-17
US62/862,432 2019-06-17
PCT/US2020/038177 WO2020257309A1 (en) 2019-06-17 2020-06-17 Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity

Publications (3)

Publication Number Publication Date
JP2022536935A JP2022536935A (ja) 2022-08-22
JP2022536935A5 true JP2022536935A5 (cg-RX-API-DMAC7.html) 2023-06-15
JP7612617B2 JP7612617B2 (ja) 2025-01-14

Family

ID=74040889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021574918A Active JP7612617B2 (ja) 2019-06-17 2020-06-17 細胞性免疫及び体液性免疫を誘導するための同種異系t細胞ベースのhivワクチン

Country Status (11)

Country Link
US (1) US20210030795A1 (cg-RX-API-DMAC7.html)
EP (1) EP3982981A4 (cg-RX-API-DMAC7.html)
JP (1) JP7612617B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220084006A (cg-RX-API-DMAC7.html)
CN (1) CN114269356A (cg-RX-API-DMAC7.html)
AU (1) AU2020294700A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025286A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143599A1 (cg-RX-API-DMAC7.html)
IL (1) IL288945A (cg-RX-API-DMAC7.html)
MX (1) MX2021015643A (cg-RX-API-DMAC7.html)
WO (1) WO2020257309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192086A1 (en) * 2021-03-06 2022-09-15 Gumrukcu Serhat Compositions and methods for treating and preventing coronavirus infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5861282A (en) * 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
US6139832A (en) * 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
US6569418B1 (en) * 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
DE60116075T4 (de) * 2000-04-25 2007-06-06 Immunex Corp., Thousand Oaks Behandlung von tumoren mit photodynamischer therapie
GB0108065D0 (en) * 2001-03-30 2001-05-23 Syngenix Ltd Viral vectors
DE602005025005D1 (de) * 2004-10-07 2011-01-05 Argos Therapeutics Inc Zusammensetzungen reifer dendritischer zellen und verfahren zu deren kultivierung
US8178291B2 (en) * 2005-02-18 2012-05-15 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors
WO2008055354A1 (en) * 2006-11-10 2008-05-15 Université de Montréal Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods
US9234175B2 (en) * 2009-11-17 2016-01-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Creating bioengineered lymph nodes
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
SG10201808811QA (en) * 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
CN107530450A (zh) * 2015-03-20 2018-01-02 宾夕法尼亚大学理事会 具有作为佐剂的cd40配体的疫苗
CA3106403A1 (en) * 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
US20220370495A1 (en) * 2019-08-21 2022-11-24 Board Of Regents, The University Of Texas System Immune cells for adoptive cell therapies

Similar Documents

Publication Publication Date Title
Westervelt et al. Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo
AU2018283811B2 (en) Poxvirus vectors encoding HIV antigens, and methods of use thereof
JP2004537974A5 (cg-RX-API-DMAC7.html)
US20240141374A1 (en) On demand expression of exogenous factors in lymphocytes
Spearman HIV vaccine development: lessons from the past and promise for the future
Zubair et al. Clinical trials and recent progress in HIV vaccine development
De Goede et al. Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection
Ao et al. Development and evaluation of an Ebola virus glycoprotein mucin-like domain replacement system as a new dendritic cell-targeting vaccine approach against HIV-1
Titti et al. Problems and emerging approaches in HIV/AIDS vaccine development
Kirchhoff et al. A novel proviral clone of HIV-2: biological and phylogenetic relationship to other primate immunodeficiency viruses
Rollman et al. The rationale behind a vaccine based on multiple HIV antigens
Young et al. Particle-based vaccines for HIV-1 infection
AU2005243730B2 (en) Method of using adenoviral vectors to induce an immune response
WO1993008836A1 (en) Induction of protection against viral infection by synergy between viral proteins and viral peptides
Lemiale et al. Lentiviral vectors for HIV disease prevention and treatment
Persson et al. Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity
zur Megede et al. A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques
Kraus et al. Characterization of a molecular clone of HIV type 2 infectious for Macaca nemestrina
AU718143B2 (en) Human immunodeficiency virus vaccines and therapeutics containing replication-impaired HIV-1 NEF-deletion mutants
WO2017088053A1 (en) Dual-action vaccines (dav) to prevent hiv and ebola virus infections
Sheppard et al. The prospects for vaccines against HIV-1: more than a field of long-term nonprogression?
Singh et al. HIV vaccine development
Zagury et al. In vitro characterization of a biologically active molecular clone of HIV-2NIH-Z containing a nef deletion and expressing a full-length transmembrane protein
Kraiselburd Biology of HIV replication
Warner et al. Human immunodeficiency virus immunotherapy using a retroviral vector